Navigating Regulatory Hurdles and Legal Challenges: ImmunityBio's Growth Trajectory

ImmunityBio reports $113M 2025 revenue, up 700%, despite FDA warning letter and legal settlements. Stock up 250% YTD as analysts forecast $195M for 2026.

ImmunityBio finds itself simultaneously addressing regulatory scrutiny, legal settlements, and the ongoing task of convincing investors of its long-term potential. The biotechnology firm's official response to a regulatory warning on April 7, 2026, comes alongside full-year 2025 financial results that provide a compelling counter-narrative to its recent difficulties.

Financial Performance Defies Headwinds

Amidst its legal and regulatory challenges, ImmunityBio reported remarkable financial growth for the 2025 fiscal year. The company achieved net revenue of $113 million, representing a staggering 700 percent increase compared to the prior year. Looking ahead, analysts at Piper Sandler project this momentum will continue, forecasting revenue to reach approximately $195 million in 2026.

The equity's performance reflects this dichotomy. Shares closed at $6.86 on April 7, marking a single-day decline of just over three percent. However, since the start of the year, the stock has advanced by more than 250 percent, dramatically outperforming the sector average gain of 0.4 percent. Market researchers remain bullish; Piper Sandler maintains an "Overweight" rating with a $12 price target, while BTIG analysts see a fair value of $13 per share.

Addressing the FDA's Compliance Concerns

The company's recent regulatory issue stems from a formal warning letter sent by the U.S. Food and Drug Administration in March 2026. The agency alleged that promotional materials for the cancer therapy Anktiva contained misleading statements regarding the drug's efficacy. Specifically, during a podcast, Executive Chairman Dr. Patrick Soon-Shiong suggested the immunotherapy could treat a broader range of cancers than its approved indication.

Anktiva is currently approved solely for patients with BCG-unresponsive non-muscle invasive bladder cancer. In response, ImmunityBio has removed the referenced podcast from its digital platforms and confirmed that a similarly cited television advertisement never aired. The company has also committed to strengthening its internal promotional compliance processes.

Legal Settlements and Pending Litigation

In a separate but concurrent development, a former employee—a documentary filmmaker—reached a settlement with the Securities and Exchange Commission for approximately $332,000. The regulator alleged she sold her shares based on material non-public information concerning negative news related to a regulatory application.

This settlement occurs during a period of heightened legal activity. Multiple investor class-action lawsuits allege the company violated securities laws during the first quarter of 2026. Investors seeking to serve as lead plaintiffs in these proceedings must come forward by May 26, 2026.

Clinical Pipeline: The Foundation for Future Expansion

The core of ImmunityBio's long-term investment thesis rests on its clinical development program. Phase 2 data from a study involving 366 patients demonstrated that Anktiva, in combination with BCG, achieved a durable complete response rate of 84 percent, compared to 52 percent for BCG alone.

The company plans to submit a Biologics License Application for the BCG-naive NMIBC indication in the fourth quarter of 2026. A supplemental application for papillary NMIBC is already under FDA review—an indication that covers a significant portion of the roughly 60,000 annual bladder cancer cases in the United States. Furthermore, approximately 580 patients are already enrolled in expanded-access programs for recombinant BCG.